News Conference News Features Opinion Conferences Slides Podcasts SACIS Voices Inside Cardiology The Heart of Success Videos All Videos Interviews Live Cases Fellows Network More Clinical Trials Education Resources Member Cases Case Library Events About Us
Specialties
Clinical Coronary Structural Endovascular Heart Failure Heart Rhythm Imaging & Physiology Policy & Practice

Trial: REBOOT-PARADOX Congress: ESC 2026

Practical Takeaways
The absence of a statistically significant mortality benefit does not rule out a mortality benefit for TAVR. Given the small sample size (80 TAVR, 40 OMT) and wide confidence intervals, substantial uncertainty remains regarding mortality estimates.